Cooper University Hospital

Silk Road Medical Expands TCAR® Portfolio with Launch of Tapered ENROUTE® Transcarotid Stent System

Retrieved on: 
Tuesday, March 5, 2024

This launch expands upon the company’s prior ENROUTE Transcarotid Stent System, offering additional configurations to better tailor the Transcarotid Artery Revascularization (TCAR) procedure to patient anatomy.

Key Points: 
  • This launch expands upon the company’s prior ENROUTE Transcarotid Stent System, offering additional configurations to better tailor the Transcarotid Artery Revascularization (TCAR) procedure to patient anatomy.
  • “New tapered configurations for our ENROUTE Transcarotid Stent System build upon the robust portfolio of Silk Road’s carotid solutions.
  • The ENROUTE Transcarotid Stent System features an optimized cell design balancing lesion coverage and anatomical conformability for long-term plaque stabilization.
  • The stent system was purpose-built for TCAR with a short delivery system for ergonomic and precise stent delivery.

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health Retains its Position as New Jersey's Only National Cancer Institute-Designated Comprehensive Cancer Center

Retrieved on: 
Tuesday, March 5, 2024

NEW BRUNSWICK, N.J., March 5, 2024 /PRNewswire/ -- Rutgers Cancer Institute of New Jersey, together with RWJBarnabas Health, the state's leading cancer center and only Comprehensive Cancer Center as recognized by the National Cancer Institute (NCI), has scored in the "exceptional" range and was redesignated by the National Cancer Institute, placing it among the top cancer centers reviewed in 2023.

Key Points: 
  • NEW BRUNSWICK, N.J., March 5, 2024 /PRNewswire/ -- Rutgers Cancer Institute of New Jersey, together with RWJBarnabas Health, the state's leading cancer center and only Comprehensive Cancer Center as recognized by the National Cancer Institute (NCI), has scored in the "exceptional" range and was redesignated by the National Cancer Institute, placing it among the top cancer centers reviewed in 2023.
  • This redesignation ensures that Rutgers Cancer Institute maintains its "Comprehensive Cancer Center" status to support the continuation of outstanding world class research and comprehensive care.
  • "For decades, Rutgers Cancer Institute has been a lifeline for those battling the cruel and relentless disease of cancer.
  • As the only NCI-Designated Comprehensive Cancer Center, Rutgers Cancer Institute is essential to the health of the people of our state and the advancement of cancer research nationally," says Congressman Frank Pallone.

Adolescent and Young Adult (AYA) Cancer Experts Unite to Form First-of-its-Kind Consortium

Retrieved on: 
Tuesday, January 30, 2024

NEW YORK, Jan. 30, 2024 /PRNewswire-PRWeb/ -- The Lymphoma Research Foundation (LRF) – the nation's largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives, and patient services – has announced the formation of its Adolescent and Young Adult (AYA) Lymphoma Consortium.

Key Points: 
  • In addition, the AYA Lymphoma Consortium and its membership will seek to support LRF's #EraseLymphoma initiative and raise awareness of the Foundation's AYA patient education efforts.
  • Both Dr. Evens and Dr. Kelly are globally recognized lymphoma researchers with a unique interest in the AYA patient population.
  • "There is a critical need to study lymphomas that occur in adolescents and young adults (AYA)," said Dr. Evens, co-chair of the AYA Lymphoma Consortium.
  • Other members of the AYA Lymphoma Consortium executive committee include pediatric oncologists, adult oncologists, laboratory and translational cancer researchers, epidemiologists, health services, survivorship, and quality of life experts from top institutions across the world.

The Inner Circle Acknowledges, Rocco Terrigno, MD as a Pinnacle Lifetime Member

Retrieved on: 
Friday, December 29, 2023

MULLICA HILL, N.J., Dec. 29, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Rocco Terrigno, MD is acknowledged as a Pinnacle Lifetime Member for his contributions to the Pulmonologist and Critical Care field.

Key Points: 
  • MULLICA HILL, N.J., Dec. 29, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Rocco Terrigno, MD is acknowledged as a Pinnacle Lifetime Member for his contributions to the Pulmonologist and Critical Care field.
  • Dr. Rocco Terrigno a renowned pulmonologist and critical care intensivist, is making a significant impact in the field of respiratory medicine.
  • Dr. Terrigno's expertise encompasses a wide range of respiratory conditions, including cough, interstitial lung disease/sarcoid, COPD/emphysema, asthma, sleep disorders, lung nodules, pleural disease, respiratory failure, and COVID-19 pneumonia.
  • Currently, Dr. Terrigno serves as a fellowship-trained pulmonologist and critical care intensivist in the Department of Critical Care Medicine at Cooper University Hospital in Camden, New Jersey.

MBrace Therapeutics Announces Initiation of Patient Dosing in Phase 1 Clinical Trial Evaluating Investigational Antibody-Drug Conjugate MBRC-101

Retrieved on: 
Tuesday, December 19, 2023

MBrace™ Therapeutics, Inc. (“MBrace”), a clinical-stage biopharmaceutical company devoted to improving the lives of patients with cancer by developing novel antibody-drug conjugates (ADCs), today announced the successful initiation of patient dosing in its Phase 1/1b study evaluating MBRC-101 in patients with advanced metastatic solid tumors refractory to standard treatment.

Key Points: 
  • MBrace™ Therapeutics, Inc. (“MBrace”), a clinical-stage biopharmaceutical company devoted to improving the lives of patients with cancer by developing novel antibody-drug conjugates (ADCs), today announced the successful initiation of patient dosing in its Phase 1/1b study evaluating MBRC-101 in patients with advanced metastatic solid tumors refractory to standard treatment.
  • This first-in-human Phase 1/1b clinical trial ( NCT06014658 ) is a multicenter, open-label, dose-escalation and dose-expansion study of MBRC-101 in patients with advanced metastatic solid tumors refractory to standard treatment.
  • The primary objectives of the study are to determine the following parameters for MBRC-101: potential optimal biologically relevant doses (OBRD), maximum tolerated dose (MTD), safety profile, and anti-tumor activity.
  • “SPARTA is a robust antibody and target discovery platform which, by overcoming several limitations of previous approaches, accelerates translation into clinical applications.

Route 92 Medical Announces Impressive Clinical Results for its Tenzing® Technology.

Retrieved on: 
Tuesday, November 14, 2023

SAN MATEO, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Route 92 Medical, a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced compelling results from a multicenter clinical study 1 on the Tenzing® 7 Delivery Catheter published in Stroke: Vascular and Interventional Neurology.

Key Points: 
  • SAN MATEO, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Route 92 Medical, a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced compelling results from a multicenter clinical study 1 on the Tenzing® 7 Delivery Catheter published in Stroke: Vascular and Interventional Neurology.
  • "Early clinical and in vitro experiences have always shown the potential of the Tenzing 7 delivery catheter.
  • "These findings underline our unwavering commitment to elevating patient outcomes through the development of best-in-class neurovascular intervention tools,” said Joey D. English, MD, PhD, Chief Medical Officer at Route 92 Medical.
  • Tenzing is a major advance.”
    For more information about Route 92 Medical and the Tenzing 7 Delivery Catheter, visit www.route92medical.com .

MBrace Therapeutics Presents Preclinical Data Demonstrating Potential of Novel Antibody Drug Conjugate at 2023 San Antonio Breast Cancer Symposium

Retrieved on: 
Thursday, December 7, 2023

MBrace Therapeutics, Inc. (“MBrace”), a clinical-stage biopharmaceutical company devoted to improving the lives of cancer patients through the development of antibody-drug conjugates (ADCs) against novel oncology targets, today announced new preclinical data supporting ongoing development for lead investigational ADC therapeutic, MBRC-101, at the San Antonio Breast Cancer Symposium taking place December 5-9, 2023, in San Antonio, Texas.

Key Points: 
  • MBrace Therapeutics, Inc. (“MBrace”), a clinical-stage biopharmaceutical company devoted to improving the lives of cancer patients through the development of antibody-drug conjugates (ADCs) against novel oncology targets, today announced new preclinical data supporting ongoing development for lead investigational ADC therapeutic, MBRC-101, at the San Antonio Breast Cancer Symposium taking place December 5-9, 2023, in San Antonio, Texas.
  • In the data presented today, robust and selective EphA5 expression was detected in greater than 80% of triple negative breast cancer (TNBC) and greater than 80% of HR+ breast cancer tissue samples.
  • EphA5 expression was not detected in adjacent, non-malignant breast tissue or normal breast.
  • Details of the poster presentation are as follows:
    Presenter: Fernanda Staquicini, Ph.D., Director of Research & Development, MBrace Therapeutics

Haystack Oncology and Rutgers Cancer Institute Collaborate to use Haystack MRD™ in Clinical Study of Early-Stage Triple-Negative Breast Cancer

Retrieved on: 
Thursday, December 14, 2023

Rutgers Cancer Institute together with RWJBarnabas Health is the state's only National Cancer Institute-designated Comprehensive Cancer Center.

Key Points: 
  • Rutgers Cancer Institute together with RWJBarnabas Health is the state's only National Cancer Institute-designated Comprehensive Cancer Center.
  • "We're excited to work with Rutgers Cancer Institute in their efforts to optimize therapeutic strategies for patients with early-stage breast cancer," said Dan Edelstein, Vice President and General Manager of Haystack Oncology.
  • "With unparalleled sensitivity, Haystack MRD provides a tool for anticipating and evaluating treatment-related benefits to a greater depth than standard clinical and radiographic metrics, making it well-equipped to support clinical studies such as this, which are essential for advancing cancer care."
  • "Triple-negative breast cancer is a subtype of breast cancer that is aggressive by nature with a complex biology, therefore, the disease tends to have a worse prognosis," said Mridula George, MD , associate program director of Breast Medical Oncology at Rutgers Cancer Institute and principal investigator of the study, which is also open at select RWJBarnabas Health sites across New Jersey.

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health to Showcase Expansive Portfolio of Hematology/Oncology Data at the 65th American Society of Hematology Annual Meeting and Exposition

Retrieved on: 
Tuesday, November 28, 2023

NEW BRUNSWICK, N.J., Nov. 28, 2023 /PRNewswire/ -- Physician-scientists from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health will present an extensive array of hematology/oncology data from their clinical research program at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, being held in San Diego, California (and virtually) from December 9-12, 2023. A total of 36 abstracts have been accepted, comprising clinical data and analyses that advance the understanding, treatment, and prognosis of blood cancers such as lymphoma, leukemia, and myeloma. Rutgers Cancer Institute of New Jersey, in partnership with RWJBarnabas Health, is New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center and the leading cancer program in the state.

Key Points: 
  • Rutgers Cancer Institute of New Jersey, in partnership with RWJBarnabas Health, is New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center and the leading cancer program in the state.
  • "As the leading cancer program in the state, our commitment to advancing oncology care is unwavering.
  • The primary endpoint was progression-free survival (PFS), and secondary endpoints included overall survival (OS), event-free survival (EFS), and safety.
  • The full list of presentations at this year's ASH Annual Meeting and Exposition follows:

Diakonos Oncology Awarded FDA Fast Track Designation for Innovative Dendritic Cell Vaccine for Glioblastoma

Retrieved on: 
Tuesday, October 17, 2023

Diakonos Oncology Corporation (“Diakonos”), a clinical stage immuno-oncology company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s unique dendritic cell vaccine, DOC1021.

Key Points: 
  • Diakonos Oncology Corporation (“Diakonos”), a clinical stage immuno-oncology company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s unique dendritic cell vaccine, DOC1021.
  • The designation was based on positive preliminary safety and efficacy data from a Phase 1 clinical trial enrolling patients with glioblastoma multiforme (GBM).
  • FDA Fast Track designation is intended to speed development and review of drugs that show early clinical promise in treating severe or life-threatening conditions.
  • This pivotal designation can help propel Diakonos closer to delivering DOC1021 to GBM patients, of which only 7% survive more than five years.